Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.
Radionetics Oncology has raised $52.5M in total funding. The most recent round was Series A. The last funding was announced in August 2023.
Radionetics Oncology's investors include 5AM Ventures, Frazier Healthcare Partners, DCVC Bio, Frazier Life Sciences, Crinetics Pharmaceuticals.
Radionetics Oncology is headquartered in California City, United States.
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.
Radionetics Oncology is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Radionetics Oncology — Funding & Investors." VCBacked, August 14, 2023, https://www.vcbacked.co/company/radionetics-oncology. Accessed August 1, 2026.
VCBacked. (2023). Radionetics Oncology — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/radionetics-oncology
{{cite web |title=Radionetics Oncology — Funding & Investors |url=https://www.vcbacked.co/company/radionetics-oncology |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated